Literature DB >> 6407392

In vitro antimicrobial activity of eight new beta-lactam antibiotics against penicillin-resistant Neisseria gonorrhoeae.

S B Kerbs, J R Stone, S W Berg, W O Harrison.   

Abstract

Increasing numbers of cases of penicillin-resistant gonorrhea necessitate the evaluation of new antibiotics for treatment of this disease. We tested the susceptibility of 92 penicillinase-producing (PP) Neisseria gonorrhoeae isolates and 88 penicillin-susceptible (PS) isolates to eight new beta-lactam antibiotics. The minimal inhibitory concentrations of these antibiotics were determined by the agar plate method. PP and PS N. gonorrhoeae isolates were susceptible to clinically achievable levels of all antibiotics tested. There were, however, marked differences among the drugs with regard to the concentration required to inhibit growth. The PP N. gonorrhoeae isolates were extremely susceptible to ceftriaxone, ceftizoxime, and cefotaxime, highly susceptible to moxalactam and cefoperazone, and less susceptible to cefoxitin, ceforanide, and cefonicid (geometric mean minimal inhibitory concentrations were 0.002, 0.003, 0.007, 0.03, 0.07, 0.6, 2.4, and 3.1 micrograms/ml, respectively). Although this in vitro study showed PP N. gonorrhoeae isolates to be comparatively more susceptible to ceftriaxone, ceftizoxime, and cefotaxime than to the other antibiotics, these results may not correlate with clinical efficacy.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6407392      PMCID: PMC184696          DOI: 10.1128/AAC.23.4.541

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  21 in total

1.  Pharmacokinetics of cefotaxime.

Authors:  K P Fu; P Aswapokee; I Ho; C Matthijssen; H C Neu
Journal:  Antimicrob Agents Chemother       Date:  1979-11       Impact factor: 5.191

2.  Penicillinase-producing Neisseria gonorrhoeae.

Authors:  W A Ashford; R G Golash; V G Hemming
Journal:  Lancet       Date:  1976-09-25       Impact factor: 79.321

3.  Cefoperazone: absorption, excretion, distribution, and metabolism.

Authors:  K Shimizu
Journal:  Clin Ther       Date:  1980       Impact factor: 3.393

4.  Spectinomycin as primary treatment of gonorrhea in areas of high prevalence of penicillinase-producing Neisseria gonorrhoeae.

Authors:  S W Berg; W O Harrison
Journal:  Sex Transm Dis       Date:  1981 Jan-Mar       Impact factor: 2.830

5.  In vitro antimicrobial activity of cefoperazone, cefotaxime, moxalactam (LY127935), azlocillin, mezlocillin, and other beta-lactam antibiotics against Neisseria gonorrhoeae and Haemophilus influenzae, including beta-lactamase-producing strains.

Authors:  C N Baker; C Thornsberry; R N Jones
Journal:  Antimicrob Agents Chemother       Date:  1980-04       Impact factor: 5.191

6.  Cefoxitin as a single-dose treatment for urethritis caused by penicillinase-producing Neisseria gonorrhoeae.

Authors:  S W Berg; M E Kilpatrick; W O Harrison; J A McCutchan
Journal:  N Engl J Med       Date:  1979-09-06       Impact factor: 91.245

7.  Comparative susceptibility of penicillinase-positive and -negative Neisseria gonorrhoeae to 30 antibiotics.

Authors:  W H Hall; E A Schierl; J E Maccani
Journal:  Antimicrob Agents Chemother       Date:  1979-04       Impact factor: 5.191

8.  Comparative in vitro activities of cefotaxime and ceftizoxime (FK749): new cephalosporins with exceptional potency.

Authors:  D Greenwood; N Pearson; A Eley; F O'Grady
Journal:  Antimicrob Agents Chemother       Date:  1980-03       Impact factor: 5.191

9.  Novel method for detection of beta-lactamases by using a chromogenic cephalosporin substrate.

Authors:  C H O'Callaghan; A Morris; S M Kirby; A H Shingler
Journal:  Antimicrob Agents Chemother       Date:  1972-04       Impact factor: 5.191

10.  In vitro activity of Ro 13-9904, cefuroxime, cefoxitin, and ampicillin against Neisseria gonorrhoeae.

Authors:  T T Yoshikawa; S A Shibata; P Herbert; P A Oill
Journal:  Antimicrob Agents Chemother       Date:  1980-08       Impact factor: 5.191

View more
  10 in total

Review 1.  Optimum therapy for acute pelvic inflammatory disease.

Authors:  M G Dodson
Journal:  Drugs       Date:  1990-04       Impact factor: 9.546

2.  In vitro activity of Ro 15-8074, a new oral cephalosporin, against Neisseria gonorrhoeae.

Authors:  W S Ng; P Y Chau; Y K Leung; P C Wong
Journal:  Antimicrob Agents Chemother       Date:  1985-09       Impact factor: 5.191

3.  Influence of inoculum size on comparative susceptibilities of penicillinase-positive and -negative Neisseria gonorrhoeae to 31 antimicrobial agents.

Authors:  W H Hall; B J Opfer
Journal:  Antimicrob Agents Chemother       Date:  1984-08       Impact factor: 5.191

4.  The potential uses of ceftriaxone.

Authors:  W M Scheld
Journal:  Eur J Clin Microbiol       Date:  1983-10       Impact factor: 3.267

Review 5.  Ceforanide. A review of its antibacterial activity, pharmacokinetic properties and clinical efficacy.

Authors:  D M Campoli-Richards; T E Lackner; J P Monk
Journal:  Drugs       Date:  1987-10       Impact factor: 9.546

Review 6.  Cefonicid. A review of its antibacterial activity, pharmacological properties and therapeutic use.

Authors:  E Saltiel; R N Brogden
Journal:  Drugs       Date:  1986-09       Impact factor: 9.546

7.  Ceftizoxime interpretive criteria for in vitro susceptibility tests with Neisseria gonorrhoeae.

Authors:  M S Barrett; R N Jones; M E Erwin
Journal:  J Clin Microbiol       Date:  1993-09       Impact factor: 5.948

8.  In vitro activity of ceftriaxone, cefetamet (Ro 15-8074), ceftetrame (Ro 19-5247; T-2588), and fleroxacin (Ro 23-6240; AM-833) versus Neisseria gonorrhoeae and Haemophilus ducreyi.

Authors:  N M Le Saux; L A Slaney; F A Plummer; A R Ronald; R C Brunham
Journal:  Antimicrob Agents Chemother       Date:  1987-07       Impact factor: 5.191

9.  In vitro activity of selected antimicrobial agents against penicillinase producing Neisseria gonorrhoeae (PPNG) and non-PPNG strains.

Authors:  D J Waghorn; B S Azadian; C Talboys
Journal:  Genitourin Med       Date:  1986-12

Review 10.  Moxalactam (latamoxef). A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  A A Carmine; R N Brogden; R C Heel; J A Romankiewicz; T M Speight; G S Avery
Journal:  Drugs       Date:  1983-10       Impact factor: 9.546

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.